Effect of Cyclosporine on the Pharmacokinetics of Colchicine in Healthy Subjects

References

• . Richette P, Bardin T. Colchicine for the treatment of gout. Expert Opin Pharmacother. 2010;11(17):2933–2938
   PubMed Web of Science ®Google Scholar
• . Harris CM, Lloyd DC, Lewis J. The prevalence and prophylaxis of gout in England. J Clin Epidemiol. 1995;48(9):1153–1158
   PubMedGoogle Scholar
• . Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29(11):2403–2406
   PubMed Web of Science ®Google Scholar
• . Choi HK, Mount DB, Reginato AM; American College of Physicians; American Physiological Society. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499–516
   PubMed Web of Science ®Google Scholar
• . Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3(8):443–449
   PubMedGoogle Scholar
• . Zhu Y, Pandya B, Choi H. Increasing gout prevalence in the US over the last two decades: the National Health and Nutrition Examination Survey (NHANES) [abstract]. Arthritis Rheum. 2010;62( suppl 10):S2154
   Google Scholar
• . Abbott KC, Kimmel PL, Dharnidharka V, Oglesby RJ, Agodoa LY, Caillard S. New-onset gout after kidney transplantation: incidence, risk factors and implications. Transplantation. 2005;80(10):1383–1391
   PubMed Web of Science ®Google Scholar
• . Abdelrahman M, Rafi A, Ghacha R, Youmbissi JT, Qayyum T, Karkar A. Hyperuricemia and gout in renal transplant recipients. Ren Fail. 2002;24(3):361–367
   PubMed Web of Science ®Google Scholar
• . Neal DA, Tom BD, Gimson AE, Gibbs P, Alexander GJ. Hyperuricemia, gout, and renal function after liver transplantation. Transplantation. 2001;72(10):1689–1691
   PubMed Web of Science ®Google Scholar
• . Stamp L, Searle M, O'Donnell J, Chapman P. Gout in solid organ transplantation: a challenging clinical problem. Drugs. 2005; 65(18):2593–2611
   PubMedGoogle Scholar
• . Gores PF, Fryd DS, Sutherland DE, Najarian JS, Simmons RL. Hyperuricemia after renal transplantation. Am J Surg. 1988;156(5): 397–400
   PubMedGoogle Scholar
• . Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321(5):287–292
   PubMed Web of Science ®Google Scholar
• . Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation. 1991;52(1):64–67
   PubMedGoogle Scholar
• . Delaney V, Sumrani N, Daskalakis P, Hong JH, Sommer BG. Hyperuricemia and gout in renal allograft recipients. Tranplant Proc. 1992;24(5):1773–1774
   PubMedGoogle Scholar
• . Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med. 1992;92(2):141–146
   PubMed Web of Science ®Google Scholar
• . Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8( suppl 1):S2
   PubMed Web of Science ®Google Scholar
• . Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984;77(4):652–656
   PubMed Web of Science ®Google Scholar
• . Mazzali M. Uric acid and transplantation. Semin Nephrol. 2005;25(1): 50–55
   PubMedGoogle Scholar
• . Stamp L, Ha L, Searle M, O'Donnell J, Frampton C, Chapman P. Gout in renal transplant recipients. Nephrology (Carlton). 2006; 11(4):367–371
   PubMedGoogle Scholar
• . Hernández—Molina G, Gachafeiro—Vilar A, Villa AR, Alberú J, Rull—Gabayet M. Gout in renal allograft recipients according to the pretransplant hyperuricemic status. Transplantation. 2008; 86(11):1543–1547
   PubMedGoogle Scholar
• . Shohat M, Halpern GJ. Familial Mediterranean fever—a review. Genet Med. 2011;13(6):487–498
   PubMed Web of Science ®Google Scholar
• . Cohen SL, Boner G, Shmueli A, Yusim A, Rosenfeld J, Shapira Z. Cyclosporin: poorly tolerated in familial Mediterranean fever. Nephrol Dial Transplant. 1989;4(3):201–204
   PubMedGoogle Scholar
• . Colcrys® (colchicine, USP) tablets for oral use [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company, Inc.; 2012. http://www.colcrys.com/assets/pdf/COLCRYS_Full_Prescribing_Information.pdf. March 14, 2012. Accessed April 25, 2012
   Google Scholar
• . Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW. Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226–2237
   PubMed Web of Science ®Google Scholar
• . Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout fare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62(4):1060–1068
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. 2006. Accessed February 21, 2012
   Google Scholar
• . US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies—Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072119.pdf. 2012. Accessed February 21, 2012
   Google Scholar
• . Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316(25):1562–1568
   PubMed Web of Science ®Google Scholar
• . Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol. 1991;18(2):264–269
   PubMed Web of Science ®Google Scholar
• . Cook M, Ramos E, Peterson J, Croker B. Colchicine neuromyopathy in a renal transplant patient with normal muscle enzyme levels. Clin Nephrol. 1994;42(1):67–68
   PubMedGoogle Scholar
• . Rieger EH, Halasz NA, Wahlstrom HE. Colchicine neuromyopathy after renal transplantation. Transplantation. 1990;49(6):1196–1198
   PubMedGoogle Scholar
• . Tapal MF. Colchicine myopathy. Scand J Rheumatol. 1996; 25(2):105–106
   PubMed Web of Science ®Google Scholar
• . Rana SS, Giuliani MJ, Oddis CV, Lacomis D. Acute onset of colchicine myoneuropathy in cardiac transplant recipients: case studies of three patients. Clin Neurol Neurosurg. 1997;99(4):266–270
   PubMedGoogle Scholar
• . Wluka AE, Ryan PF, Miller AM, . Post-cardiac transplantation gout: incidence of therapeutic complications. J Heart Lung Transplant. 2000;19(10):951–956
   PubMedGoogle Scholar
• . Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipients: how little is too much? J Rheumatol. 2000;27 (6):1334–1337
   PubMedGoogle Scholar
• . Twentyman PR. Cyclosporins as drug resistance modifiers. Biochem Pharmacol. 1992;43(1):109–117
   PubMed Web of Science ®Google Scholar
• . Gruberg L, Har—Zahav Y, Agranat O, Freimark D. Acute myopathy induced by colchicine in a cyclosporin treated heart transplant recipient: possible role of the multidrug resistance transporter. Transplant Proc. 1999;31(5):2157–2158
   PubMedGoogle Scholar
• . Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo. Hepatology. 1992;15(5):899–903
   PubMedGoogle Scholar
• . Speeg KV, Maldonado AL, Liaci J, Muirhead D. Effect of cyclosporine on colchicine secretion by a kidney multidrug transporter studied in vivo. J Pharmacol Exp Ther. 1992;261(1):50–55
   PubMedGoogle Scholar
• . Ducloux D, Schuller V, Bresson—Vautrin C, Chalopin JM. Colchicine myopathy in renal transplant recipients on cyclosporin. Nephrol Dial Transplant. 1997;12(11):2389–2392
   PubMedGoogle Scholar